Form 4 for SPRY ARS Pharmaceuticals, Inc.
Accepted 2022-02-02 00:00:00 ET · period of report 2022-02-01 · accession 0001209191-22-006437 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-02-02 | 2022-02-01 | SPRY | Piazza Jonathan | CFO | A - Grant | $0.00 | +11.2K | 25.5K | +79% | $0 |
| DM | 2022-02-02 | 2022-02-01 | SPRY | Piazza Jonathan | CFO | A - Grant | $0.00 | +110.2K | 42.8K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-01 | A | A | 11,250 | $0.00 | 25,534 | D | — | — | (F1) The shares being reported are being issued pursuant to restricted stock units, each one of which represents a contingent right to receive one share of the Issuer's common stock. (F2) Includes 2,054 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan (the "ESPP") on June 30, 2021 and 326 shares acquired under the ESPP on December 31, 2021. |
| 2 | Derivative | Stock Option (right to buy) | 2022-02-01 | A | A | 67,500 | $0.00 | 67,500 | D | $4.85 · — to 2032-01-31 | 67,500 Common Stock | (F3) The shares subject to the option vest in equal monthly installments over the 48 months following February 1, 2022. |
| 3 | Derivative | Stock Option (right to buy) | 2022-02-01 | A | A | 42,750 | $0.00 | 42,750 | D | $4.85 · — to 2032-01-31 | 42,750 Common Stock | (F4) 25% of the shares subject to the option vest on February 1, 2023, and the remaining shares will vest monthly thereafter over three years. |